Retrophin Inc (NASDAQ:RTRX) Director Steve Aselage sold 10,000 shares of Retrophin stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $20.00, for a total transaction of $200,000.00. Following the completion of the transaction, the director now directly owns 238,732 shares of the company's stock, valued at $4,774,640. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Steve Aselage also recently made the following trade(s):
- On Thursday, May 14th, Steve Aselage sold 3,062 shares of Retrophin stock. The shares were sold at an average price of $15.09, for a total transaction of $46,205.58.
- On Tuesday, May 12th, Steve Aselage sold 1,000 shares of Retrophin stock. The shares were sold at an average price of $17.16, for a total transaction of $17,160.00.
Shares of Retrophin stock traded up $0.17 during trading on Monday, reaching $19.73. The company's stock had a trading volume of 505,375 shares, compared to its average volume of 464,282. The business's 50-day moving average price is $16.23 and its 200-day moving average price is $15.33. The firm has a market cap of $844.12 million, a PE ratio of -8.05 and a beta of 0.81. Retrophin Inc has a 52 week low of $8.98 and a 52 week high of $21.95. The company has a quick ratio of 5.88, a current ratio of 5.97 and a debt-to-equity ratio of 0.92.
Retrophin (NASDAQ:RTRX) last announced its earnings results on Monday, May 11th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.68) by $0.70. The company had revenue of $47.77 million during the quarter, compared to analysts' expectations of $43.14 million. Retrophin had a negative net margin of 57.01% and a negative return on equity of 43.15%. Equities analysts predict that Retrophin Inc will post -1.56 earnings per share for the current year.
A number of brokerages have recently weighed in on RTRX. Zacks Investment Research raised shares of Retrophin from a "hold" rating to a "buy" rating and set a $16.00 price target for the company in a research note on Monday, May 4th. BTIG Research assumed coverage on shares of Retrophin in a research report on Tuesday, June 16th. They issued a "buy" rating and a $25.00 target price for the company. BMO Capital Markets upped their target price on shares of Retrophin from $33.00 to $34.00 and gave the company an "outperform" rating in a research note on Tuesday, May 12th. BidaskClub upgraded shares of Retrophin from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, Canaccord Genuity reiterated a "buy" rating and set a $26.00 target price on shares of Retrophin in a research report on Tuesday, May 19th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company's stock. Retrophin presently has an average rating of "Buy" and a consensus target price of $26.50.
A number of hedge funds have recently bought and sold shares of the stock. AXA raised its stake in Retrophin by 19.3% in the first quarter. AXA now owns 197,400 shares of the biopharmaceutical company's stock valued at $2,880,000 after purchasing an additional 32,000 shares in the last quarter. Invesco Ltd. raised its stake in Retrophin by 54.0% in the first quarter. Invesco Ltd. now owns 26,646 shares of the biopharmaceutical company's stock valued at $389,000 after purchasing an additional 9,349 shares in the last quarter. Atom Investors LP raised its stake in Retrophin by 26.8% in the first quarter. Atom Investors LP now owns 190,136 shares of the biopharmaceutical company's stock valued at $2,774,000 after purchasing an additional 40,135 shares in the last quarter. Janus Henderson Group PLC acquired a new position in Retrophin in the first quarter valued at about $2,322,000. Finally, Massachusetts Financial Services Co. MA raised its stake in Retrophin by 18.8% in the first quarter. Massachusetts Financial Services Co. MA now owns 88,425 shares of the biopharmaceutical company's stock valued at $1,290,000 after purchasing an additional 13,995 shares in the last quarter.
Retrophin Company Profile
Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
See Also: What is the Current Ratio?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
6 Gambling Stocks Ready For a Rebound
If you didn’t believe that gambling stocks are a worthwhile investment, consider this. The Business Research Company projects the global gambling market to reach $565.4 billion through 2022. That assumes that the industry will continue growing at is annual rate of 5.9%.
The gambling industry is composed of many segments. There are casinos, lotteries, and the now legalized segment of sports betting. But gambling is also broken down into offline gambling, online gambling and even virtual reality gambling. In fact, virtual reality gambling is projected to grow at an annual rate of 21.5% until 2022.
But virtual reality is only one of a number of emerging technologies that are changing the “traditional” face of the gambling industry. There are now hybrid games – the combination of online and land-based games and even augmented reality games.
And don’t forget about fantasy sports. Fantasy sports has created an entire industry and it wasn’t created for one person to have bragging rights over their buddies. Fantasy sports is a multi-million industry.
But like many other segments of the economy, gambling stocks were hit hard by the Covid-19 pandemic. Not only were casinos closed, but live sports were also put on hold. This dried up many of the traditional avenues of gambling, and gambling stocks sank lower as a result.
However, the global economy is starting to re-open. And while it was thought that casinos would be one of the last to come back, there are casinos that are starting to re-open. And, it’s becoming more and more likely that there will be live sports (likely without fans initially) sooner rather than later. And that will open up the fantasy sports market.
These stocks tend to move quickly. So now is the time to take action. That’s why we’ve created this special presentation that highlights 6 gambling stocks that are ready for a rebound. The sell-off was real, but so will the comeback. And when it does, these stocks may cost much more than they do now.
View the "6 Gambling Stocks Ready For a Rebound".